Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...
14h
Onco360(R) Has Been Selected as the National Pharmacy Partner for UNLOXCYT(TM) (cosibelimab-ipdl)
Onco360(R) , the nation's leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Sun Pharmaceuticals for UNLOXCYT(TM) (cosibelimab-ipdl). UNLOXCYT is the first ...
January 15, 2026) - Nanjing Leads Biolabs Co., Ltd. (HKE: 9887) ("Leads Biolabs" or the "Company") today announced that Opamtistomig (LBL-024), its core investigational PD-L1/4-1BB bispecific antibody ...
US Oncologists anticipate rapid biosimilar uptake – up to 50% of PD-1/PD-L1 eligible patients within the first year – while ...
Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...
Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), ...
Zacks Investment Research on MSN
Will Keytruda continue to aid Merck's top line in Q4 earnings?
A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...
Zymeworks (ZYME) posts strong Phase 3 Ziihera data in HER2+ GEA and eyes up to $440M in milestones plus royalties—read the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback